tiprankstipranks
Trending News
More News >
Lexicon Pharmaceuticals (LXRX)
:LXRX
Advertisement

Lexicon Pharmaceuticals (LXRX) AI Stock Analysis

Compare
1,661 Followers

Top Page

LX

Lexicon Pharmaceuticals

(NASDAQ:LXRX)

Rating:58Neutral
Price Target:
$1.50
▲(21.95%Upside)
The overall stock score of 58 reflects a mixed outlook for Lexicon Pharmaceuticals. The most significant strengths are the positive momentum and strategic partnerships indicated in the earnings call. However, financial performance remains a concern due to ongoing losses, negative cash flows, and poor valuation metrics.
Positive Factors
Financial Position
The exclusive licensing agreement with Novo Nordisk for LX9851 in obesity is potentially worth up to $1 billion.
Pipeline Advancement
Lexicon is well-positioned to successfully advance its diverse pipeline of innovative small-molecule inhibitors.
Regulatory Approval
Results from the inTandem studies led to the approval of ZYNQUISTA (sotagliflozin) for the management of T1D by the EMA.
Negative Factors
Clinical Efficacy Concerns
The path forward for pilavapadin is viewed with caution due to modest efficacy versus placebo in the Ph.2b PROGRESS study.
Execution Risks
There are remaining execution risks across LXRX's clinical pipeline and anticipated cash burn.

Lexicon Pharmaceuticals (LXRX) vs. SPDR S&P 500 ETF (SPY)

Lexicon Pharmaceuticals Business Overview & Revenue Model

Company DescriptionLexicon Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of breakthrough treatments for human diseases. The company operates primarily in the biotechnology and pharmaceuticals sectors, with a mission to innovate in the field of drug discovery and development. Lexicon's core products include therapies for diabetes, carcinoid syndrome, and other metabolic and rare diseases, leveraging their proprietary genetics-based approach to identify and develop new drug candidates.
How the Company Makes MoneyLexicon Pharmaceuticals generates revenue through the commercialization of its pharmaceutical products and through strategic partnerships with other companies in the biotechnology and pharmaceutical industries. Revenue streams primarily consist of sales of its marketed products, such as Xermelo, a treatment for carcinoid syndrome diarrhea, as well as collaborative agreements that provide research funding, milestone payments, and royalties. These partnerships often involve licensing Lexicon's proprietary technologies or compounds to larger pharmaceutical companies, which can accelerate the development and commercialization of new therapies. Additionally, Lexicon may receive government grants or other funding to support its research and development efforts.

Lexicon Pharmaceuticals Earnings Call Summary

Earnings Call Date:May 13, 2025
(Q1-2025)
|
% Change Since: 95.24%|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment Positive
The call presented a generally positive outlook for Lexicon Pharmaceuticals, with significant achievements such as the Novo Nordisk partnership and successful Phase 2B results for pilavapadin. Financial restructuring has been effective, although there are ongoing costs associated with R&D. The sentiment is overall positive with strong strategic positioning and reduced losses.
Q1-2025 Updates
Positive Updates
Exclusive License Agreement with Novo Nordisk
Lexicon announced an exclusive license agreement with Novo Nordisk for LX9851, potentially worth up to $1 billion, including an upfront payment of $45 million received in April 2025.
Phase 2B Study Success for Pilavapadin
Lexicon identified a well-tolerated dose for pilavapadin in their Phase 2B study, demonstrating clear evidence of effect for Phase 3 studies.
Improved Financial Position
Lexicon improved their balance sheet by reducing operating costs, using the upfront payment from Novo Nordisk to reduce debt, and ending the quarter with $194.8 million in cash and short-term investments.
Strong Progress with Sotagliflozin
Lexicon remains on track with enrollment in the SONATA HCM study of sotagliflozin, with confidence in its potential for both obstructive and non-obstructive HCM.
Successful Restructuring and Cost Reduction
Selling, general and administrative expenses decreased significantly to $11.6 million from $32.1 million in Q1 2024 due to strategic repositioning.
Negative Updates
Increased R&D Expenses
Research and development expenses increased to $15.3 million from $14.4 million in the same period in 2024, reflecting late-stage development program costs.
Continued Net Loss
Lexicon reported a net loss of $25.3 million for Q1 2025, compared to a net loss of $48.4 million in the same period in 2024.
Company Guidance
During the Lexicon Pharmaceuticals first quarter 2025 financial results conference call, the company provided several forward-looking statements and updates on their drug programs. Key metrics included a license agreement with Novo Nordisk for LX9851, with Lexicon eligible for up to $1 billion in milestone payments and $75 million in upfront and near-term payments, of which $45 million was already received. The company also reported a net loss of $25.3 million for the quarter, down from $48.4 million the previous year, and ended the quarter with $194.8 million in cash and short-term investments. Operating expenses for 2025 are expected to be between $135 million and $145 million. Progress was highlighted in their pilavapadin and sotagliflozin programs, with a focus on advancing Phase 3 studies and ongoing strategic partnerships to expand their global footprint.

Lexicon Pharmaceuticals Financial Statement Overview

Summary
Lexicon Pharmaceuticals faces ongoing profitability challenges, with limited revenue growth and negative margins. While the balance sheet shows manageable debt levels, the equity position has weakened. Cash flow difficulties persist with negative operational and free cash flows, indicating potential liquidity concerns.
Income Statement
40
Negative
Lexicon Pharmaceuticals shows limited revenue growth with a TTM increase of only 0.43% compared to the previous annual period. Gross profit margins remain strong at 98.03% for TTM, but the company struggles with negative EBIT and net profit margins due to high operational expenses, reflecting ongoing losses and profitability challenges.
Balance Sheet
50
Neutral
The company's balance sheet reveals a moderate debt-to-equity ratio of 0.34, indicating manageable debt levels against equity. However, stockholders' equity has decreased over time, and the equity ratio stands at 41.33%, showing a decline in assets financed by equity. The firm maintains a reasonable cash position, but there are concerns regarding the negative equity from previous years.
Cash Flow
45
Neutral
The cash flow statement highlights a negative free cash flow growth rate, with free cash flows worsening by 6.32% in TTM. Operating cash flow remains negative, leading to a challenging cash position. The free cash flow to net income ratio is negative due to ongoing losses, indicating potential cash flow issues.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue31.08M1.20M139.00K298.00K24.00M
Gross Profit30.46M1.12M-288.00K-54.75M22.07M
EBITDA-184.29M-163.46M-98.74M-86.66M-41.10M
Net Income-200.40M-177.12M-103.13M-88.27M-70.18M
Balance Sheet
Total Assets298.42M229.43M194.30M136.91M203.79M
Cash, Cash Equivalents and Short-Term Investments237.96M170.03M138.36M86.74M152.28M
Total Debt108.40M106.06M55.29M2.28M12.81M
Total Liabilities152.47M136.32M77.17M23.31M47.42M
Stockholders Equity145.95M93.11M117.12M-1.49B156.37M
Cash Flow
Free Cash Flow-179.81M-162.37M-90.18M-88.24M-143.06M
Operating Cash Flow-178.78M-161.90M-88.85M-87.02M-142.97M
Investing Cash Flow-15.38M-49.94M-71.08M2.11M380.76M
Financing Cash Flow238.35M187.96M142.21M22.71M-147.64M

Lexicon Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.23
Price Trends
50DMA
0.79
Positive
100DMA
0.65
Positive
200DMA
0.86
Positive
Market Momentum
MACD
0.14
Negative
RSI
65.60
Neutral
STOCH
81.07
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LXRX, the sentiment is Positive. The current price of 1.23 is above the 20-day moving average (MA) of 0.99, above the 50-day MA of 0.79, and above the 200-day MA of 0.86, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 65.60 is Neutral, neither overbought nor oversold. The STOCH value of 81.07 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LXRX.

Lexicon Pharmaceuticals Risk Analysis

Lexicon Pharmaceuticals disclosed 38 risk factors in its most recent earnings report. Lexicon Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Lexicon Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
PLPLX
62
Neutral
$115.43M34.5210.42%0.18%-55.15%
58
Neutral
$446.71M-86.09%1250.63%37.24%
57
Neutral
$341.69M322.49%-30.66%36.48%
54
Neutral
$271.24M-198.47%-38.86%
52
Neutral
$7.35B-0.07-63.71%2.81%16.17%0.03%
45
Neutral
$492.59M-32.12%10.98%
35
Underperform
$386.41M-500.57%81.94%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
LXRX
Lexicon Pharmaceuticals
1.23
-0.88
-41.71%
PLX
Protalix
1.45
0.34
30.63%
DBVT
DBV Technologies SA - American
10.00
5.38
116.45%
GOSS
Gossamer Bio
1.70
0.64
60.38%
FHTX
Foghorn Therapeutics
6.13
-0.16
-2.54%
TERN
Terns Pharmaceuticals
5.64
-2.90
-33.96%

Lexicon Pharmaceuticals Corporate Events

Delistings and Listing ChangesStock SplitRegulatory Filings and Compliance
Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension
Neutral
Jul 3, 2025

On July 3, 2025, Lexicon Pharmaceuticals received a letter from Nasdaq indicating eligibility for an additional 180-day period to regain compliance with the minimum $1 bid price requirement for its common stock. The company applied to transfer its stock from the Nasdaq Global Select Market to the Nasdaq Capital Market, which was approved, and the transfer will occur on July 7, 2025. This move allows Lexicon Pharmaceuticals more time to meet the bid price requirement, with plans to potentially implement a reverse stock split if necessary.

The most recent analyst rating on (LXRX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lexicon Pharmaceuticals stock, see the LXRX Stock Forecast page.

Executive/Board ChangesShareholder MeetingsStock Split
Lexicon Pharmaceuticals Holds Annual Stockholder Meeting
Neutral
Jun 3, 2025

On June 2, 2025, Lexicon Pharmaceuticals held its annual meeting of stockholders to vote on several key proposals. The meeting resulted in the election of Class I Directors, amendments to the company’s equity incentive plans, approval of a potential reverse stock split, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2025. These decisions reflect strategic moves to enhance corporate governance and financial management, potentially impacting shareholder value and market perception.

The most recent analyst rating on (LXRX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Lexicon Pharmaceuticals stock, see the LXRX Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 17, 2025